康柏西普联合玻璃体切割术治疗增生性糖尿病视网膜病变的疗效分析

发布时间：2018-03-03 01:04

本文选题：康柏西普　切入点：玻璃体切除术　出处：《湖南师范大学学报(医学版)》2016年06期 　论文类型：期刊论文

【摘要】：目的 :探讨康柏西普联合玻璃体切割术治疗增生性糖尿病视网膜病变的疗效。方法 :本研究选取了100例增生性糖尿病视网膜病变,年龄27~68岁,对照组(47例)单纯给予玻璃体切割术治疗,康柏西普组(53例)采用玻璃体切除术前3~6天眼内注射康博西普治疗。通过对患者术前术后6个月最佳矫正视力(BCVA),术前,术后3个月、6个月黄斑中心凹厚度,随访6个月期间并发症情况进行记录,评价康柏西普联合玻璃体切割术治疗增生性糖尿病视网膜病变的疗效。结果 :术前两组BCVA相比,差异没有统计学意义;术后6个月,康博西普组和对照组BCVA均明显提高,且康博西普组BCVA高于对照组,与术前相比,术后3个月,6个月的黄斑中心凹厚度均明显变薄。随访6个月期间,康博西普组并发症发生率明显低于对照组。结论 :康柏西普联合玻璃体切割术治疗增生性糖尿病视网膜病变可有效改善视力,减轻黄斑水肿症状,术后并发症较少。
[Abstract]:Objective: to investigate the effect of Compacipe combined with vitrectomy in the treatment of proliferative diabetic retinopathy. Methods: 100 cases of proliferative diabetic retinopathy, aged 2768 years, were selected in this study. The control group (47 cases) were treated with vitrectomy alone, and the control group (53 cases) were treated by intraocular injection of Combosemide 3 ~ 6 days before vitrectomy. The best corrected visual acuity (BCV) was obtained 6 months before and 6 months after vitrectomy. The thickness of macular fovea was 3 months and 6 months after operation. The complications were recorded during the follow-up of 6 months to evaluate the curative effect of Compactopril combined with vitrectomy in the treatment of proliferative diabetic retinopathy. Results: BCVA was compared between the two groups before and after operation. At 6 months after operation, the BCVA in the Combolipe group and the control group were significantly increased, and the BCVA in the Combolipe group was higher than that in the control group, which was higher than that in the preoperative group. The thickness of macular fovea became thinner at 3 months and 6 months after operation. Conclusion: Combortopril combined with vitrectomy for proliferative diabetic retinopathy can effectively improve visual acuity and alleviate macular edema symptoms.
【作者单位】：咸阳市第一人民医院眼科;
【基金】：陕西省卫生科研项目(NO.2014E12)
【分类号】：R587.2;R779.6

【相似文献】